This study investigated the mRNA expression pattern and distribution of 5-hydroxytryptamine (5-HT) receptors 5-HT2A, 5-HT2B, 5-HT3A, 5-HT4, and 5-HT7 within the urothelium and detrusor of normal bladder tissue and in the urothelium of bladders from patients with benign prostatic hyperplasia (BPH).
Normal urinary bladder specimens were obtained from 13 patients undergoing radical cystectomy due to bladder cancer (normal group) and BPH specimens were obtained from 27 benign prostatic obstruction patients receiving transurethral prostatectomy or retropubic prostatectomy. Receptor subtype mRNA expression was determined by real-time reverse transcription polymerase chain reaction on urothelium, detrusor, and whole mucosal preparations. Receptor distribution was determined by immunohistochemistry.
In normal tissues, expressions of 5-HT2B and 5-HT7 receptor mRNAs in the urothelium, detrusor, and whole mucosa were greater than the average expression for all receptor subtype mRNAs. 5-HT2B receptor protein was distributed in the apical urothelium and among the detrusor smooth muscle layers. In contrast, the 5-HT7 receptors were within the urothelium middle cell layers and detrusor smooth muscle cells. The expression pattern of each 5-HT receptor subtype mRNA within the BPH urothelium was similar to that in the normal urothelium. The expression level of 5-HT2A receptor mRNA in the BPH group was significantly lower than the normal group; however, the expressions of both 5-HT3A and 5-HT7 mRNAs were significantly higher. The expressions of both 5-HT2B and 5-HT4 mRNAs were not significantly different between the normal and BPH groups.
In normal urinary bladders, the expressions of both 5-HT2B and 5-HT7 mRNAs were higher compared to the 5-HT2A, 5-HT3A, and 5-HT4 mRNAs. The distributions of 5-HT2B and 5-HT7 receptors were different in the urothelium and detrusor layers. The 5-HT3A and 5-HT7 receptor mRNAs in the BPH group were significantly higher compared to the normal urothelium, while the 5-HT2A mRNA was significantly lower.
Asahi Kasei Pharma Corporation.
Advances in therapy. 2015 Sep 21 [Epub ahead of print]
Tetsuya Imamura, Osamu Ishizuka, Teruyuki Ogawa, Tomonori Minagawa, Masakuni Ishikawa, Shiro Hiragata, Hitoshi Yokoyama, Masaki Nakazawa, Yoshiki Kurizaki, Osamu Nishizawa
Department of Lower Urinary Tract Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. Department of Lower Urinary Tract Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. , Department of Urology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. , Department of Urology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. , Department of Urology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. , Department of Urology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. , Department of Urology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. , Department of Urology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. , Department of Urology, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. , Department of Lower Urinary Tract Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.